The Association Between IL-22 And IL-22R1 With The Clinical Characterizes And Prognosis In Ovarian Serous Cystadenocarcinoma

Objectives: So far,the study of the role of IL-22 and IL-22R1 in ovarian serous cystic adenocarcinoma has not been reported.In this study,immunohistochemical assay was used to detect the expression of protein molecular biomarkers IL-22 and their receptor IL-22R1 in normal ovarian tissues,ovarian serous cystic adenoma tissues and ovarian serous cystic adenocarcinoma tissues,the relationship between IL-22 and its receptor IL-22R1 and clinicopathological factors and prognosis in patients with ovarian serous cystic adenocarcinoma was analyzed by statistical method.Methods: This study collected the clinical data of 123 patients who underwent gynecological surgery in the first affiliated Hospital of China Medical University in January 2007-December 2011,and all the cases were complete with pathological data,all of which were confirmed by pathology,and were not treated by neoadjuvant chemotherapy and radiotherapy before operation.Immunohistochemical assay was used to detect the expression of IL-22 and its receptor IL-22R1 in 93 cases of ovarian serous cystic adenocarcinoma,23 cases of ovarian serous cystic adenoma and 7 cases of ovarian tissue.The relationship between IL-22 and IL-22R1 and clinicopathological factors and prognosis of ovarian serous cystic adenocarcinoma was analyzed by using card-square test,Spearman correlation test,Kaplan–meier and Log-rank test.The score of immunohistochemical staining used the double semiquantitative scoring method.Positive cell percentage scoring criteria:zero points(0-5%);one point(6%-25%);two point(26%-50%);three point(>50%);Staining intensity scoring criteria:zero point(no stain);one point(weak stain);tow point(moderate stain);three point(strong stain).Staining intensity score multiplied by the positive cell percentage score as the final score.The controversial part was judged by a third pathologist,with two experienced pathologists grading all tissue slices and grading all tissue sections according to the new pathological grading of ovarian cancer.Statistical analyses were performed with SPSS PASW Statistics v.18.0(IBM,Chicago,IL).and Graph Pad Prism 5 statistics software(La Jolla,CA,USA).P<0.05 was considered significance.Results:(1)The expression of IL-22 in ovarian serous cystic adenocarcinoma was significantly higher than that of normal ovarian tissue(p<0.01)and ovarian serous cystic adenoma(p<0.01),the expression of IL-22R1 in ovarian serous cystic adenocarcinoma was significantly higher than that of normal ovarian tissue(p<0.01)and ovarian serous cystic adenoma(p<0.01),the expression of IL-22 and-IL-22R1 in ovarian serous cystic adenocarcinoma was positively correlated(p<0.01);(2)IL-22 and IL-22R1 were positively correlated with ovarian cancer FIGO stage(P<0.01)and serum CA125 level(p<0.05),and the expression of IL-22 and IL-22R1 was not significantly correlated with age(P>0.05)and pathological grading(P>0.05);(3)There was no significant difference(P >0.05)between the Over-all survival time and the Disease-free survival time in patients with IL-22 and IL-22R1 positive expression Group and IL-22 and IL-22R1 negative expression group.Conclusions: The expression of IL-22 and IL-22R1 in ovarian serous cystic adenocarcinoma was significantly higher than that of ovarian serous cystic adenoma and normal ovarian tissue,and the expression of IL-22 and IL-22R1 in ovarian serous cystic adenocarcinoma was positively correlated,in addition IL-22 and IL-22R1 are positively correlated with the operative pathological staging and serum CA125 level of ovarian carcinoma,It is indicated that IL-22 can be used as a valuable marker for diagnosing and monitoring the recurrence of ovarian serous cystic adenocarcinoma by combining with IL-22R1 and participating in the development of ovarian serous cystic carcinoma.